BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 26695861)

  • 1. Implications of Androgen Assay Accuracy in the Phenotyping of Women With Polycystic Ovary Syndrome.
    Tosi F; Fiers T; Kaufman JM; Dall'Alda M; Moretta R; Giagulli VA; Bonora E; Moghetti P
    J Clin Endocrinol Metab; 2016 Feb; 101(2):610-8. PubMed ID: 26695861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Defining hyperandrogenism in polycystic ovary syndrome: measurement of testosterone and androstenedione by liquid chromatography-tandem mass spectrometry and analysis by receiver operator characteristic plots.
    Barth JH; Field HP; Yasmin E; Balen AH
    Eur J Endocrinol; 2010 Mar; 162(3):611-5. PubMed ID: 20008514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of body mass index on measured and calculated androgen parameters in adult women with Hirsutism and PCOS.
    Cupisti S; Dittrich R; Binder H; Kajaia N; Hoffmann I; Maltaris T; Beckmann MW; Mueller A
    Exp Clin Endocrinol Diabetes; 2007 Jun; 115(6):380-6. PubMed ID: 17701884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Testosterone to dihydrotestosterone ratio as a new biomarker for an adverse metabolic phenotype in the polycystic ovary syndrome.
    Münzker J; Hofer D; Trummer C; Ulbing M; Harger A; Pieber T; Owen L; Keevil B; Brabant G; Lerchbaum E; Obermayer-Pietsch B
    J Clin Endocrinol Metab; 2015 Feb; 100(2):653-60. PubMed ID: 25387259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgen Profile Through Life in Women With Polycystic Ovary Syndrome: A Nordic Multicenter Collaboration Study.
    Pinola P; Piltonen TT; Puurunen J; Vanky E; Sundström-Poromaa I; Stener-Victorin E; Ruokonen A; Puukka K; Tapanainen JS; Morin-Papunen LC
    J Clin Endocrinol Metab; 2015 Sep; 100(9):3400-7. PubMed ID: 26192874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Total body fat and central fat mass independently predict insulin resistance but not hyperandrogenemia in women with polycystic ovary syndrome.
    Tosi F; Di Sarra D; Kaufman JM; Bonin C; Moretta R; Bonora E; Zanolin E; Moghetti P
    J Clin Endocrinol Metab; 2015 Feb; 100(2):661-9. PubMed ID: 25393642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Measurement of selected androgens using liquid chromatography-tandem mass spectrometry in reproductive-age women with Type 1 diabetes.
    Gunness A; Pazderska A; Ahmed M; McGowan A; Phelan N; Boran G; Taylor AE; O'Reilly MW; Arlt W; Moore K; Behan LA; Sherlock M; Gibney J
    Hum Reprod; 2018 Sep; 33(9):1727-1734. PubMed ID: 30020477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Divergences in insulin resistance between the different phenotypes of the polycystic ovary syndrome.
    Moghetti P; Tosi F; Bonin C; Di Sarra D; Fiers T; Kaufman JM; Giagulli VA; Signori C; Zambotti F; Dall'Alda M; Spiazzi G; Zanolin ME; Bonora E
    J Clin Endocrinol Metab; 2013 Apr; 98(4):E628-37. PubMed ID: 23476073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The association of body mass index and biochemical hyperandrogenaemia in women with and without polycystic ovary syndrome.
    Yasmin E; Balen AH; Barth JH
    Eur J Obstet Gynecol Reprod Biol; 2013 Feb; 166(2):173-7. PubMed ID: 23102586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Defining Hyperandrogenism in Women With Polycystic Ovary Syndrome: A Challenging Perspective.
    Pasquali R; Zanotti L; Fanelli F; Mezzullo M; Fazzini A; Morselli Labate AM; Repaci A; Ribichini D; Gambineri A
    J Clin Endocrinol Metab; 2016 May; 101(5):2013-22. PubMed ID: 26964728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic inflexibility is a feature of women with polycystic ovary syndrome and is associated with both insulin resistance and hyperandrogenism.
    Di Sarra D; Tosi F; Bonin C; Fiers T; Kaufman JM; Signori C; Zambotti F; Dall'Alda M; Caruso B; Zanolin ME; Bonora E; Moghetti P
    J Clin Endocrinol Metab; 2013 Jun; 98(6):2581-8. PubMed ID: 23596136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Opposing effects of dehydroepiandrosterone sulfate and free testosterone on metabolic phenotype in women with polycystic ovary syndrome.
    Lerchbaum E; Schwetz V; Giuliani A; Pieber TR; Obermayer-Pietsch B
    Fertil Steril; 2012 Nov; 98(5):1318-25.e1. PubMed ID: 22835450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can the source of hyperandrogenism in adolescents with polycystic ovary syndrome predict metabolic phenotype?
    Al Nofal A; Viers LD; Javed A
    Gynecol Endocrinol; 2017 Nov; 33(11):882-887. PubMed ID: 28649885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of steroidogenic pathways among normoandrogenic and hyperandrogenic polycystic ovary syndrome patients and normal cycling women.
    Medeiros SF; Barbosa JS; Yamamoto MM
    J Obstet Gynaecol Res; 2015 Feb; 41(2):254-63. PubMed ID: 25256274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperandrogenemia predicts metabolic phenotype in polycystic ovary syndrome: the utility of serum androstenedione.
    O'Reilly MW; Taylor AE; Crabtree NJ; Hughes BA; Capper F; Crowley RK; Stewart PM; Tomlinson JW; Arlt W
    J Clin Endocrinol Metab; 2014 Mar; 99(3):1027-36. PubMed ID: 24423344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperandrogenism in women with polycystic ovary syndrome persists after menopause.
    Markopoulos MC; Rizos D; Valsamakis G; Deligeoroglou E; Grigoriou O; Chrousos GP; Creatsas G; Mastorakos G
    J Clin Endocrinol Metab; 2011 Mar; 96(3):623-31. PubMed ID: 21177795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measuring salivary androgens as a useful tool in the diagnosis of polycystic ovary syndrome.
    Szydlarska D; Grzesiuk W; Kondracka A; Bartoszewicz Z; Bar-Andziak E
    Endokrynol Pol; 2012; 63(3):183-90. PubMed ID: 22744623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The predictive value of total testosterone alone for clinical hyperandrogenism in polycystic ovary syndrome.
    Yang Y; Ouyang N; Ye Y; Hu Q; Du T; Di N; Xu W; Azziz R; Yang D; Zhao X
    Reprod Biomed Online; 2020 Oct; 41(4):734-742. PubMed ID: 32912651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The influence of obesity on androstenedione to testosterone ratio in women with polycystic ovary syndrome (PCOS) and hyperandrogenemia.
    Misichronis G; Georgopoulos NA; Marioli DJ; Armeni AK; Katsikis I; Piouka AD; Saltamavros AD; Roupas ND; Panidis D
    Gynecol Endocrinol; 2012 Apr; 28(4):249-52. PubMed ID: 21970600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CAG repeat polymorphism in androgen receptor gene is not directly associated with polycystic ovary syndrome but influences serum testosterone levels.
    Skrgatic L; Baldani DP; Cerne JZ; Ferk P; Gersak K
    J Steroid Biochem Mol Biol; 2012 Feb; 128(3-5):107-12. PubMed ID: 22107839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.